Ovid Therapeutics (OVID) – Research Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Ovid Therapeutics (NASDAQ: OVID):

• 10/15/2026 – Ovid Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/15/2026 – Ovid Therapeutics is now covered by Wolfe Research. They set an “outperform” rating and a $5.00 price target on the stock.
• 10/15/2026 – Ovid Therapeutics is now covered by Wolfe Research. They set an “outperform” rating and a $5.00 price target on the stock.
• 10/9/2026 – Ovid Therapeutics is now covered by Cantor Fitzgerald. They set an “overweight” rating on the stock.
• 10/6/2026 – Ovid Therapeutics is now covered by Guggenheim. They set a “buy” rating and a $7.00 price target on the stock.
• 10/5/2026 – Ovid Therapeutics is now covered by Guggenheim. They set a “buy” rating and a $7.00 price target on the stock.
• 9/11/2026 – Ovid Therapeutics had its “buy” rating reaffirmed by UBS Group AG.
• 9/11/2026 – Ovid Therapeutics had its price target raised by HC Wainwright from $4.00 to $5.00. They now have a “buy” rating on the stock.
• 9/3/2026 – Ovid Therapeutics had its “buy” rating reaffirmed by Roth Capital. They now have a $8.00 price target on the stock.

Ovid Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines for rare neurological disorders, including epilepsies and neurodevelopmental conditions. The company’s research programs are designed to address diseases with significant unmet medical needs and limited treatment options.

Ovid has developed a pipeline of investigational therapies targeting the underlying biology of neurological disorders. Its programs have included treatments for seizure disorders such as Dravet syndrome and Lennox-Gastaut syndrome, as well as potential therapies for other rare epileptic and neurodevelopmental conditions.